Comments
Shares of biotechnology major Biocon gained 3 per cent today after its research arm Syngene International received capital markets regulator SEBI’s approval to launch an initial public offer (IPO).
Biocon stock had climbed as much as 2.93 per cent to Rs 460 on the BSE. On the NSE, it rose 3 per cent to Rs 460 in morning trade.
At 12.15 pm, the stock was up 1.56 per cent or Rs 6.95 at Rs 453.85 on the BSE. On the NSE, it was up 1.68 per cent or Rs 7.50 at Rs 454.05.
The company had filed its draft red herring prospectus with SEBI through its lead merchant banker Axis Capital in April.
Securities and Exchange Board of India issued its final observations on the draft offer documents on June 12, which is necessary for companies to launch any public offer.
As per the draft papers, the company plans to sell 22 million equity shares, including reservation of up to two million shares for Biocon shareholders, through an offer for sale.
While the company did not comment on the amount to be raised through the IPO, sources said it could be around Rs 600 crore.
Of the total shares on offer, 50 per cent has been reserved for qualified institutional buyers, 15 per cent for high net worth individuals and the rest for retail investors.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.